Magic bullets or novel multimodal drugs with various CNS targets for Parkinson's disease?

Nature Reviews Drug Discovery

Volumn 6, Issue 6, 2007, Pages

  Youdim, Moussa B H ^a   Van der Schyf, Cornelis J ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 8 (3 CHLOROSTYRYL)CAFFEINE; ACETYLCHOLINESTERASE; ADENOSINE A2A RECEPTOR ANTAGONIST; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE; IRON; IRON CHELATING AGENT; ISTRADEFYLLINE; LADOSTIGIL; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; OXIDOPAMINE; RASAGILINE; UNCLASSIFIED DRUG; VK 28;

ALZHEIMER DISEASE; CLINICAL TRIAL; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LETTER; NERVE CELL NECROSIS; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BLOCKING; SUBSTANTIA NIGRA;

EID: 34447544101     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2330     Document Type: Letter

References (12)

1. Schapira, A. H. et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nature Rev. Drug Discov. 5 845-854 (2006).
2. Braak, H. et al. Pathology associated with sporadic Parkinson's disease - where does it end? J. Neural Transm. Suppl. 70, 89-97 (2006).
3. Van der Schyf, C. J., Gal, S., Geldenhuys, W. J. & Youdim, M. B. H. Multifunctional neu roprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin. Invest. Drugs 15, 873-886 (2006).
4. Youdim, M. B. H., Maruyama, W. & Nao i, M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO -B inhibitor antiparkinsonian drug, rasagiline. Drugs Today 41, 369-391 (2005).
5. Sagi, Y., Mandel, S., Amit, T. & Youdim, M. B. Activation of tyrosin e kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post -MPTP-induced parkinsonism. Neurobiol. Dis. 25, 35-44 (2007).
6. Youdim, M. B. H., Amit, T., Bar -Am, O., Weinreb, O. & Yogev-Falach, M. Implications of co -morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective -neurorescue drugs; Ladostigil. Neurotox. Res. 10, 181-192 (2006).
7. Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R. & Crichton, R. R. Iron, brain ageing and neurodegenerative disorders. Nature Rev. Neurosci. 5, 863-873 (2004).
8. Avramovich-Tirosh, Y. et al. Therapeutic targets and potential of the novel brain -permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem. 100, 490-502 (2007).
9. Chen, J. F. et al. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A recepto r antagonism. J. Biol. Chem. 277, 36040-36044 (2002).
10. Castagnoli, N. Jr. et al. Monoamine oxidase B inhibition and neuroprotection: Studies on selective adenosine A2A receptor antagonists. Neurology 61 (Suppl. 6), 62-68 (2003).
11. Petzer, J. P. et al. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorg. Med. Chem. 11, 1299-1310 (2003).
12. Van der Schyf, C. J., Geldenhuys, W. J. & Youdim, M. B. Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J. Neurochem. 99, 1033-1048 (2006).